Diligence memo · auto-generated · as of July 2, 2026
Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Psycheceutical Bioscience, Inc. operates in Biotech, based in Fort Lauderdale.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Psycheceutical Bioscience, Inc. has raised $7.3M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.1M on 2012-07-01.
Most recent recorded round closed around 2024-06-20.
Valuation (modeled)modeled
Provath models Psycheceutical Bioscience, Inc. at approximately $493K (range $72K–$1.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.04× the median modeled value of Seed Biotech companies in 2022–2024 (6 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 29 months.
Last raise 2.0 yr ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotech peers (233 compared).
Modeled value ranks above 68% of those peers.
Closest niche peers: Yemaachi, INVO Bioscience, Inc., General Genomics Inc., MET Biotechnology Inc., J3 Bioscience, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.